Sanara MedTech (NASDAQ:SMTI) Announces Earnings Results, Beats Estimates By $0.18 EPS

Sanara MedTech (NASDAQ:SMTI) announced its quarterly earnings data on Monday. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.18, FiscalAI reports. The company had revenue of $27.80 million during the quarter, compared to analysts’ expectations of $26.80 million. Sanara MedTech had a negative net margin of 36.42% and a negative return on equity of 20.73%.

Sanara MedTech Stock Performance

Shares of SMTI stock traded down $0.38 during mid-day trading on Monday, hitting $18.02. 34,353 shares of the stock were exchanged, compared to its average volume of 58,410. The stock’s fifty day simple moving average is $18.82 and its two-hundred day simple moving average is $21.74. The stock has a market capitalization of $165.15 million, a price-to-earnings ratio of -4.26 and a beta of 1.16. The company has a debt-to-equity ratio of 7.75, a quick ratio of 1.59 and a current ratio of 1.80. Sanara MedTech has a 12-month low of $16.05 and a 12-month high of $35.95.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on SMTI shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sanara MedTech in a report on Tuesday, April 21st. Wall Street Zen lowered Sanara MedTech from a “buy” rating to a “hold” rating in a research report on Sunday, April 5th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of Sanara MedTech in a research report on Monday, January 26th. Lake Street Capital began coverage on Sanara MedTech in a research note on Wednesday, April 15th. They set a “buy” rating and a $32.00 price target on the stock. Finally, Zacks Research cut Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $34.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SMTI. Squarepoint Ops LLC lifted its stake in shares of Sanara MedTech by 56.0% in the 4th quarter. Squarepoint Ops LLC now owns 48,953 shares of the company’s stock worth $1,143,000 after acquiring an additional 17,570 shares during the period. Hsbc Holdings PLC purchased a new stake in Sanara MedTech in the 2nd quarter valued at approximately $382,000. Jane Street Group LLC purchased a new position in shares of Sanara MedTech during the 4th quarter worth approximately $355,000. JPMorgan Chase & Co. increased its holdings in shares of Sanara MedTech by 26.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,057 shares of the company’s stock valued at $351,000 after purchasing an additional 2,315 shares in the last quarter. Finally, NewEdge Advisors LLC acquired a new position in Sanara MedTech during the fourth quarter worth about $243,000. 8.10% of the stock is currently owned by hedge funds and other institutional investors.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.